You are not logged in
You need to be a member to print this page.
Sign up for free membership, or log in.
Find out more about our membership benefits
2008, Volume 15, Supplement 2
NEWS
Br J Cardiol 2008;15(Suppl 2):S2
Introduction
The management of cardiovascular risk is a huge area for debate, involving a multitude of factors, disciplines and guidelines. The Cardiodiabetes Forum, sponsored by MSD...
NEWS
Br J Cardiol 2008;15(Suppl 2):S3-S5
Translating cholesterol guidelines for the treatment of patients at high risk of cardiovascular disease into practice
Current guidelines for primary and secondary prevention of...
NEWS
Br J Cardiol 2008;15(Suppl 2):S6-S7
The use of surrogate end points in cardiovascular disease and diabetes
What is a surrogate end point? Research, particularly intervention trials, can only be appropriately interpreted with pre-defined end points. The hypothesis being tested will be...
NEWS
Br J Cardiol 2008;15(Suppl 2):S8-S10
Cardiodiabetes – is a joint approach the way forward?
Diabetes is a known, independent, risk factor for cardiovascular disease and since diabetes and serious cardiovascular disease are frequently observed together, the term ‘cardiodiabetes’ is...
NEWS
Br J Cardiol 2008;15(Suppl 2):S11-S13
New versus old cardiometabolic markers of risk
New biomarkers, with the potential to serve as indicators of cardiovascular risk, are continually emerging. The validity of several of these was examined by this...
NEWS
Br J Cardiol 2008;15(Suppl 2):S14-S15
Managing cardiovascular risk in ‘at-risk’ populations
Cardiovascular risk assessment is currently very topical, with much debate about measurement and targets. Recent guidelines from the National Institute for Health and Clinical Excellence...